Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

LEXICON PHARMACEUTICALS, INC.

(LXRX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/15/2019 08/16/2019 08/19/2019 08/20/2019 08/21/2019 Date
1.32(c) 1.37(c) 1.41(c) 1.32(c) 1.4271 Last
784 499 614 361 702 360 538 821 532 867 Volume
-8.97% +3.79% +2.92% -6.38% +8.11% Change
More quotes
Financials (USD)
Sales 2019 43,9 M
EBIT 2019 -72,1 M
Net income 2019 -87,7 M
Debt 2019 180 M
Yield 2019 -
Sales 2020 101 M
EBIT 2020 -82,7 M
Net income 2020 -101 M
Debt 2020 158 M
Yield 2020 -
P/E ratio 2019 -1,63x
P/E ratio 2020 -1,46x
EV / Sales2019 7,29x
EV / Sales2020 2,96x
Capitalization 140 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
08/12LEXICON PHARMACEUTICALS : to Present at Upcoming Investor Conference
AQ
08/09LEXICON PHARMACEUTICALS : Announces Publication of Positive Data for Zynquista o..
AQ
08/09Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
GL
08/08Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista&..
GL
08/01LEXICON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
07/31LEXICON : 2Q Earnings Snapshot
AQ
07/31LEXICON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (f..
AQ
07/31LEXICON PHARMACEUTICALS : Reports Second Quarter 2019 Financial Results and Prov..
AQ
07/31Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Pro..
GL
07/30LEXICON PHARMACEUTICALS : Announces Date Change for Second Quarter 2019 Financia..
AQ
More news
Analyst Recommendations on LEXICON PHARMACEUTICALS, I
More recommendations
Sector news : Bio Therapeutic Drugs
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
08/07NOVARTIS : Medicare Moves to Cover Costly Cell Therapies
DJ
More sector news : Bio Therapeutic Drugs
Chart LEXICON PHARMACEUTICALS, INC.
Duration : Period :
Lexicon Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LEXICON PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 8,00  $
Last Close Price 1,32  $
Spread / Highest target 1 188%
Spread / Average Target 506%
Spread / Lowest Target 127%
EPS Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & Executive Vice President
Frank P. Palantoni Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICALS, INC.-78.77%140
GILEAD SCIENCES1.42%80 344
VERTEX PHARMACEUTICALS10.87%47 223
REGENERON PHARMACEUTICALS-20.74%32 392
GENMAB28.01%13 210
NEUROCRINE BIOSCIENCES, INC.35.88%8 886